Therapy related acute myeloid leukemia secondary to CAR-T therapy in refractory/relapsed multiple myeloma patient showing poor prognosis
Sign Up to like & getrecommendations! Published in 2025 at "Annals of Hematology"
DOI: 10.1007/s00277-025-06310-4
Abstract: There has been a growing concern regarding the adverse events including hematological malignancies which occurring in the later stages following CAR-T immunotherapy. Here, we presented a case of secondary MDS/AML following CAR-T immunotherapy in our… read more here.
Keywords: poor prognosis; therapy; car immunotherapy; refractory relapsed ... See more keywords
An Innovative PTD-IVT-mRNA Delivery Platform for CAR Immunotherapy of ErbB(+) Solid Tumor Neoplastic Cells
Sign Up to like & getrecommendations! Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10112885
Abstract: Chimeric antigen receptor (CAR) immunotherapy includes the genetic modification of immune cells to carry such a receptor and, thus, recognize cancer cell surface antigens. Viral transfection is currently the preferred method, but it carries the… read more here.
Keywords: ivt mrna; delivery platform; car; car immunotherapy ... See more keywords